Sign Up to like & get
recommendations!
1
Published in 2022 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-022-06929-3
Abstract: Treatment with the tyrosine kinase inhibitor (TKI) imatinib in patients with gastrointestinal stromal tumours (GIST) causes symptoms that could negatively impact health-related quality of life (HRQoL). Treatment-related symptoms are usually clinician-reported and little is known…
read more here.
Keywords:
gist patients;
forum;
treatment;
forum data ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Journal of Gastrointestinal Cancer"
DOI: 10.1007/s12029-019-00324-8
Abstract: Little is known about the sporadic coincidence of gastrointestinal stromal tumors (GISTs) with second primary tumors (SPTs). The aim of this study is to clarify if there is a clinicopathologic correlation responsible for the synchronous…
read more here.
Keywords:
gist patients;
gastrointestinal stromal;
stromal tumors;
systematic reviews ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2023 at "Journal of gastroenterology and hepatology"
DOI: 10.1111/jgh.16165
Abstract: BACKGROUND Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor with high prevalence of KIT and PDGFRA mutations. Few effective treatments can be exploited in imatinib or sunitinib resistant cases. While in immunotherapy, application…
read more here.
Keywords:
kit a502;
a502 y503;
gist patients;
chinese gist ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Oxidative Medicine and Cellular Longevity"
DOI: 10.1155/2023/3619306
Abstract: Background The overall risk of cardiovascular mortality (CVM) in cancer survivors has increased with time. The trend of CVM in patients with gastrointestinal stromal tumors (GISTs) remains unclear. This study is aimed at assessing the…
read more here.
Keywords:
cvm;
cardiovascular;
gist patients;
mortality ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Diagnostic Pathology"
DOI: 10.1186/s13000-021-01172-6
Abstract: Background Many studies reporting that down-regulation of SOCS6 plays vital roles in promoting progression of malignant tumors have been published. The present study was performed to evaluate whether SOCS6 was significantly associated with prognosis of…
read more here.
Keywords:
analysis;
expression;
gist patients;
socs6 ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e22511
Abstract: e22511 Background: Gastrointestinal stromal tumour (GIST) is one of the most common soft tissue sarcoma subtypes. Regorafenib is the approved third line treatment after imatinib and sunitinib. Often GIST patients have an altered gastro-intestinal tract…
read more here.
Keywords:
non significant;
exposure;
regorafenib;
gastrectomy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Neoplasma"
DOI: 10.4149/neo_2020_200301n212
Abstract: In the post-Imatinib era, the median survival of patients diagnosed with GIST has reached almost 5 years. Prolonging GIST-specific survival, GIST patients have an increased incidence of secondary neoplasia. Data on the prognostic impact of…
read more here.
Keywords:
monocentric analysis;
second primary;
retrospective monocentric;
gist ... See more keywords